Search

Displaying results 261 - 270 of 4265 in total
  1. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.

  2. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

  3. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.

  4. Drug

    Descartes-30

    go.drugbank.com/drugs/DB16361
    Investigational

    Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics.

  5. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    It is being pursued by Access Pharmaceuticals, Inc.

  6. Drug

    Tazobactam

    go.drugbank.com/drugs/DB01606
    ApprovedInvestigational

    Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.

  7. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    [L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … therapy developed by Mayne Pharma in 1992.

  8. Drug

    Pariglasgene brecaparvovec

    go.drugbank.com/drugs/DB16801
    Approved

    [L64050,L64051] It delivers a functional copy of the human G6PC gene, under the control of native G6PC promoter and enhancer elements, to hepatocytes, resulting in the production of normally functioning … Pariglasgene brecaparvovec-opnr is an adeno-associated virus serotype 8 (AAV8)–based gene therapy for glycogen storage disease type Ia (GSDIa), a disorder caused by deficiency of the enzyme glucose-6-phosphatase

  9. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  10. Drug

    Moxidectin

    go.drugbank.com/drugs/DB11431
    ApprovedInvestigationalVet approved

    [A33385] Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018.[L2970] … Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23.